Clearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Drops 70.0%

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a significant decline in short interest in October. As of October 30th, there was short interest totaling 1,160 shares, a decline of 70.0% from the October 15th total of 3,861 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily volume of 7,371 shares, the days-to-cover ratio is currently 0.2 days.

Clearmind Medicine Stock Down 3.1%

Clearmind Medicine stock traded down $0.14 during mid-day trading on Friday, reaching $4.47. The stock had a trading volume of 3,427 shares, compared to its average volume of 105,940. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 4.31. The stock’s 50-day simple moving average is $6.51 and its 200-day simple moving average is $40.24. The firm has a market capitalization of $2.28 million, a PE ratio of -0.01 and a beta of 0.88. Clearmind Medicine has a fifty-two week low of $4.35 and a fifty-two week high of $1,272.00.

Clearmind Medicine (NASDAQ:CMND) last announced its earnings results on Thursday, September 10th. The company reported ($4.56) earnings per share (EPS) for the quarter.

Clearmind Medicine Company Profile

Clearmind Medicine Inc. (NASDAQ: CMND) is a clinical-stage biotechnology company focused on discovering and developing psychedelic-derived therapeutics for underserved health conditions. The company’s research combines medicinal chemistry with the study of psychoactive compounds to identify treatments designed to address substance-use disorders and other metabolic or behavioral conditions. Clearmind’s lead investigational compound is MEAI, also known as 5-methoxy-2-aminoindane. The company has evaluated MEAI in preclinical and early clinical research for potential applications including alcohol use disorder and binge drinking.